Derma Sciences, Inc.
DSCI
NASDAQ7.00
USD
- -
- -
Derma Sciences, Inc.
DSCI
(NASDAQ)
Recent
price
7.00
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Derma Sciences, Inc. (DSCI) develops, manufactures, and markets advanced wound care products, including pharmaceutical wound care such as the investigational drug DSC127 for diabetic foot ulcers; advanced wound dressings like MEDIHONEY gel and dressings, ALGICELL Ag alginate dressings, XTRASORB superabsorbent dressings, BIOGUARD antimicrobial barrier dressings, and amniotic tissue allografts including AMNIOEXCEL and AMNIOMATRIX; traditional wound care items such as branded and private-label dressings; and specialty securement devices like Mobility1. The company, founded in 1984 and headquartered in Princeton, New Jersey, with manufacturing in Toronto, Canada, Nantong, China, and a facility in St. Louis, operates primarily in the United States, Canada, and the United Kingdom through direct sales and distributors targeting wound care centers, hospitals, extended care facilities, home health agencies, and physicians' offices. In March 2017, Integra LifeSciences Holdings Corp. completed its $205 million acquisition of Derma Sciences, integrating its amniotic tissue and wound care portfolio into Integra's regenerative technologies to expand advanced wound care offerings, with Derma Sciences products such as MEDIHONEY and Dermagran continuing under Integra as of 2025 amid ongoing product recalls for quality holds.